Revance Therapeutics Inc (RVNC)

[DewDiligence]

I'm not bullish on Q3 earnings but the market will look past Q3 if the outlook for Q4 and beyond is strong.

RVNC probably was not intending to issue revenue guidance as early as 4Q23, but the steep selloff has made it more exigent to do so.

If RVNC does issue 4Q23 guidance, I expect it to be either a lowball estimate or a loose range to minimize the probability of a miss. My own 4Q23 forecast is in #msg-173145191.